Pages that link to "Q29417046"
Jump to navigation
Jump to search
The following pages link to Common genetic variation and antidepressant efficacy in major depressive disorder: a meta-analysis of three genome-wide pharmacogenetic studies (Q29417046):
Displaying 50 items.
- major depressive disorder (Q42844) (← links)
- ESRRG (Q5401840) (← links)
- MYO10 (Q18029805) (← links)
- ITGA11 (Q18036498) (← links)
- KCNH5 (Q18038666) (← links)
- ENOX1 (Q18041520) (← links)
- Biomarkers predicting antidepressant treatment response: how can we advance the field? (Q27026147) (← links)
- Genetic prediction of antidepressant drug response and nonresponse in Korean patients (Q28543005) (← links)
- A genome-wide association study of antidepressant response in Koreans (Q28597255) (← links)
- Progress and prospects in pharmacogenetics of antidepressant drugs (Q30249569) (← links)
- Use of large data sets and the future of personalized treatment (Q30870491) (← links)
- Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response (Q31130220) (← links)
- Towards the clinical implementation of pharmacogenetics in bipolar disorder. (Q33688133) (← links)
- Gene-wide Association Study Reveals RNF122 Ubiquitin Ligase as a Novel Susceptibility Gene for Attention Deficit Hyperactivity Disorder. (Q33905738) (← links)
- Rare copy number variation in treatment-resistant major depressive disorder (Q33922682) (← links)
- Antidepressant treatment response is modulated by genetic and environmental factors and their interactions (Q33930731) (← links)
- GRIK4 polymorphism and its association with antidepressant response in depressed patients: a meta-analysis (Q34400329) (← links)
- Understanding the pharmacogenetics of selective serotonin reuptake inhibitors (Q34424865) (← links)
- Epigenetic alterations in depression and antidepressant treatment (Q34426216) (← links)
- Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans (Q34438637) (← links)
- Epigenetic mechanisms underlying the role of brain-derived neurotrophic factor in depression and response to antidepressants. (Q34864481) (← links)
- Using biomarkers to predict treatment response in major depressive disorder: evidence from past and present studies (Q35109175) (← links)
- RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response (Q35598795) (← links)
- The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. (Q35715254) (← links)
- Transcriptional dys-regulation in anxiety and major depression: 5-HT1A gene promoter architecture as a therapeutic opportunity (Q35887986) (← links)
- Genome-wide association study of antidepressant response: involvement of the inorganic cation transmembrane transporter activity pathway (Q35993192) (← links)
- Association of IL12A Expression Quantitative Trait Loci (eQTL) With Primary Biliary Cirrhosis in a Chinese Han Population (Q36993574) (← links)
- Machine learning, statistical learning and the future of biological research in psychiatry (Q37182897) (← links)
- Identifying genetic loci affecting antidepressant drug response in depression using drug-gene interaction models (Q37200660) (← links)
- DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP (Q37201357) (← links)
- TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics (Q37213132) (← links)
- A high-quality human reference panel reveals the complexity and distribution of genomic structural variants (Q37330443) (← links)
- Personalized prescribing: a new medical model for clinical implementation of psychotropic drugs (Q37344778) (← links)
- A Genome-Wide Test of the Differential Susceptibility Hypothesis Reveals a Genetic Predictor of Differential Response to Psychological Treatments for Child Anxiety Disorders. (Q37364621) (← links)
- Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options (Q37612442) (← links)
- Learned helplessness: unique features and translational value of a cognitive depression model (Q38113996) (← links)
- Pharmacogenetics of antidepressant drugs: an update after almost 20 years of research (Q38121519) (← links)
- Pharmacogenetics of mood disorders: what clinicians need to know (Q38139479) (← links)
- Value of genetic and epigenetic testing as biomarkers of response to antidepressant treatment. (Q38154916) (← links)
- Gene expression: biomarker of antidepressant therapy? (Q38154917) (← links)
- Pharmacogenetics of antidepressant treatment in obsessive-compulsive disorder: an update and implications for clinicians (Q38236029) (← links)
- Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. (Q38258243) (← links)
- Psychiatric genetics and the future of personalized treatment (Q38269350) (← links)
- Psychopharmacology and the future of personalized treatment (Q38269355) (← links)
- Genetics in child and adolescent psychiatry: methodological advances and conceptual issues (Q38410122) (← links)
- CHL1, ITGB3 and SLC6A4 gene expression and antidepressant drug response: results from the Munich Antidepressant Response Signature (MARS) study (Q38444087) (← links)
- Genome-wide association studies in pharmacogenomics of antidepressants (Q38444447) (← links)
- Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines. (Q38476909) (← links)
- BDNF/TRKB/P75NTR polymorphisms and their consequences on antidepressant efficacy in depressed patients. (Q38540142) (← links)
- Genetic mechanisms of electroconvulsive therapy response in depression. (Q38803609) (← links)